FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

127 letters match. Newest first.

  1. Huangshi Hygienic Material Medicine Co., Ltd.

    Huangshi Hygienic Material Medicine released U.S. drugs without identity and strength testing and lacked stability data for labeled expiration dates.

    High risk
  2. OSRX, Inc.

    OSRX, a Montana compounding facility, made sterile ophthalmic drugs under insanitary conditions with quality and labeling failures.

    High risk
  3. Amazon.com, Inc.

    Amazon sold unapproved numbing creams for tattoos and cosmetic procedures, FDA says.

    High risk
  4. Cosco International, Inc.

    FDA warned Cosco International over nonprescription drug manufacturing failures and unapproved drug products.

    High risk
  5. BEO Pharma Inc. dba BEO Pharmaceuticals Inc.

    FDA cited BEO Pharma for manufacturing quality violations, including missing identity testing of high-risk drug ingredients and releasing a batch before microbial testing.

    High risk
  6. Hangzhou Glamcos Biotech Co., Ltd.

    Hangzhou Glamcos Biotech’s OTC antibacterial wipes had CGMP violations and were unapproved and misbranded, FDA says.

    High risk
  7. Rite-Kem Incorporated

    FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.

    High risk
  8. TKTX USA

    FDA warned TKTX USA that its TKTX Numbing Creams are unapproved and misbranded drugs with lidocaine levels above OTC limits.

    High risk
  9. TKTX Numb Store

    FDA warned TKTX Numb Store that its lidocaine anesthetic creams are unapproved and misbranded drugs sold without a prescription.

    High risk
  10. Fagron Compounding Services, LLC dba Fagron Sterile Service

    FDA warns Fagron Sterile Services about unsafe sterile drug production and labeling problems at its Wichita facility.

    High risk
  11. Kardesler Ucan Yaglar Sanayi Anonim Sirketi

    Turkey-based OTC drug maker Kardesler Ucan failed to test glycerin, propylene glycol and ethanol for dangerous impurities and is on US import alert.

    High risk
  12. Mihon Corp. d/b/a VitalityVita and Boulla, LLC

    FDA warns Mihon Corp./Boulla that VitalityXtra, PeakMax, ZapMax and ZoomMax supplements contain hidden sildenafil and diclofenac and are unapproved, misbranded drugs.

    High risk
  13. Sombra Cosmetics, Inc.

    FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.

    High risk
  14. Brands International Corporation

    Brands International, a Canadian drug manufacturer, limited an FDA inspection and had manufacturing quality violations including mold contamination.

    High risk
  15. Dr. Brite, LLC

    FDA cited Dr. Brite for manufacturing quality failures and selling unapproved, misbranded oral care and hand sanitizer drugs.

    High risk
  16. Centura Pharmaceuticals Inc

    FDA warned Centura Pharmaceuticals that its BLT 1-2-3 Cream, a mixed numbing product for cosmetic procedures, is an unapproved new drug.

    High risk
  17. MedOffice Saglik Endustri Anonim Sirketi

    FDA warned MedOffice Saglik after an inspection found missing batch release testing and inadequate process validation for over-the-counter drugs.

    High risk
  18. Diora Kimya Sanayi ve Ticaret Limited Sirketi

    FDA cited Diora Kimya for drug manufacturing quality failures and for an unlisted antibacterial soap.

    High risk
  19. Soliteint Kozmetikai KFT

    Hungarian contract maker Soliteint Kozmetikai failed to test OTC pain-relief drugs and ingredients, FDA says; U.S. production halted.

    High risk
  20. Outin Futures Corp.

    FDA warned Outin Futures, a Korean drug manufacturer, of CGMP violations and sunscreen misbranding after a March 2024 inspection.

    High risk
  21. Makra Kozmetika D.O.O.

    FDA warns Makra Kozmetika over OTC drug manufacturing violations, including missing batch and ingredient testing, after April 2024 inspection.

    High risk
  22. Clean Solutions LLC

    FDA warned Clean Solutions LLC that its OTC hand soaps and sanitizer were adulterated because it released drugs without component or finished-product testing.

    High risk
  23. Kaylaan LLC

    FDA warns Kaylaan LLC that its fluoride toothpaste tablets were made without release testing, raw material identity testing, and adequate CGMP controls.

    High risk
  24. Media Networks Sydney Pty Limited

    Media Networks Sydney failed to properly list Mylanta 2go Antacid and Microlax Enema with FDA, making them misbranded.

    Low
  25. Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd.

    FDA warned Guangzhou Baiyunshan Jingxiutang Pharmaceutical over current good manufacturing practice violations in over-the-counter drug manufacturing, including inadequate specs and microbial testing.

    High risk
  26. YangZhou SuXiang Medical Instrument Co., Ltd.

    FDA warns YangZhou SuXiang Medical Instrument over manufacturing quality failures and import alert for OTC drugs.

    High risk
  27. Max Chemical Inc.

    FDA warned Max Chemical Inc. in San Juan, Puerto Rico, that its OTC drug manufacturing violated CGMP, making its drugs adulterated.

    High risk
  28. Aqualex Co., Ltd.

    Aqualex, a Korean contract manufacturer, was cited for manufacturing failures and an unapproved OTC sunscreen with misleading labeling.

    High risk
  29. Aruba Aloe Balm N.V.

    Aruba Aloe Balm N.V. made OTC drugs with methanol-contaminated ethanol and failed CGMP, prompting recall and import alert.

    High risk
  30. Dr Sankunni’s Ayurvedic Research Foundation Private Ltd.

    Dr Sankunni's Ayurvedic Research Foundation failed to correct drug listing and registration errors for its balms and hand sanitizer.

    Low
  31. Jiangsu Meifan Biotechnology Co. Ltd.

    FDA cites Jiangsu Meifan Biotechnology for OTC drug manufacturing-rule failures and import alert.

    High risk
  32. Ambaya Gold Health Products, LLC

    FDA warned Ambaya Gold Health Products that website and social media claims made its supplements and silver products unapproved new drugs.

    High risk
  33. Sky Bank Media, LLC dba Painless Tattoo Cream Co.

    FDA warned Painless Tattoo Cream Co. that its numbing cream and spray are unapproved new drugs with excess lidocaine.

    High risk
  34. Tattoo Numbing Cream Co.

    Tattoo Numbing Cream Co. sold Signature Tattoo Numbing Cream and Miracle Numb Spray as unapproved drugs for tattooing.

    High risk
  35. Thai Nakorn Patana Co., Ltd.

    FDA warns Thai Nakorn Patana over manufacturing quality violations, including missing identity and strength testing before release of OTC drugs.

    High risk
  36. Ningbo Poplar Daily-Use

    FDA warned Ningbo Poplar Daily-Use that its OTC drugs had manufacturing quality failures in testing, component identity checks, and stability data.

    High risk
  37. Sambrosa Care Inc.

    FDA warns Sambrosa Care that its OTC sweet dreams Night Syrup is an unapproved, misbranded drug with excessive doxylamine dosing.

    High risk
  38. Colonial Dames Company, Ltd

    FDA warns Colonial Dames of manufacturing violations and unapproved acne drug claims for Oxygenetix.

    High risk
  39. Novid Group, Inc.

    FDA told Novid Group its OTC nasal spray, novid NASAL SPRAY, is an unapproved new drug and misbranded.

    High risk
  40. AmLion Toothpaste Mfg. Sdn. Bhd.

    FDA cites AmLion Toothpaste in Malaysia for CGMP failures, including no testing of glycerin and sorbitol for DEG/EG; firm stays on import alert.

    High risk
  41. Walgreen Company

    FDA warns Walgreen Company that its Walgreens Sensitive Extra Whitening drug listing is incomplete and inaccurate.

    Low
  42. Nature’s Innovation, Inc.

    FDA warned Nature’s Innovation over unapproved drugs marketed for molluscum and shingles, including a kit for children.

    High risk
  43. Walmart, Inc

    FDA warned Walmart over selling Naturasil Molluscum Treatment Kit, an unapproved new drug for molluscum.

    High risk
  44. Centaur Pharmaceuticals Private Ltd.

    FDA says Centaur Pharmaceuticals drugs were adulterated due to inadequate cleaning and cross-contamination.

    High risk
  45. Gadget Island, Inc.

    Gadget Island sold three male enhancement products containing undeclared tadalafil and sildenafil without FDA approval.

    High risk
  46. Centaur Pharmaceuticals Private Ltd.

    FDA warns Centaur Pharmaceuticals over manufacturing practice failures in active ingredients, including records and cleaning.

    High risk
  47. Lydia Co. Ltd.

    Lydia Co. Ltd. submitted mismatched drug listing data for eight products, leading FDA to remove them from its NDC Directory.

    Low
  48. Mr. Lulu LLC

    FDA warned Mr. Lulu LLC of Claremont, California, that its OTC sunscreen drops were adulterated: no release testing, no identity testing, no batch records.

    High risk
  49. Sorcerz.com

    FDA warned Sorcerz.com for selling unapproved, misbranded opioid and benzodiazepine drugs to U.S. consumers online.

    High risk
  50. Procter & Gamble Manufactura S. de R.L. de C.V.

    FDA warned P&G Manufactura over mismatched active ingredients in the drug listing for Vicks Nyquil Severe Hot Remedy.

    Low